Key Development
Two months after Zenbexus won accelerated FDA approval on the strength of minimal residual disease, Bristol Myers Squibb now has the endpoint the market was waiting for: progression-free survival.
In the Phase 3 EXCALIBER-RRMM analysis involving 800 patients, Zenbexus/iberdomide + daratumumab + dexamethasone (ZDd) achieved median PFS of 42 months, versus 20 months with daratumumab, bortezomib and dexamethasone (DVd). The hazard ratio was 0.49, representing a 51% reduction in the risk of progression or death. Median follow-up was 23 months.
The regulatory sequence is what makes the result unusual. FDA granted Zenbexus accelerated approval on August 13, 2026 before mature PFS was available, based on an MRD-negative complete response rate of 41% versus 21% with DVd. Zenbexus became the first approved CELMoD and an important test case for using MRD directly as a surrogate to bring a new multiple myeloma therapy to market earlier.
Why It Matters
- The MRD signal has now been followed by a PFS signal. A near-doubling of MRD-negative CR is now accompanied by a PFS HR of 0.49.
- CELMoD has moved from platform promise to Phase 3 clinical validation.
- BMS is building a class, not a single asset. Mezigdomide has also produced positive Phase 3 PFS data and is under FDA review, with a May 13, 2027 target date.
- An oral backbone may have commercial advantages, particularly if it can replace injectable or more operationally burdensome components of existing regimens.
- Safety remains material. Zenbexus carries boxed warnings for embryo-fetal toxicity and serious thromboembolism, with significant neutropenia and infection risk.
Healthcare Insight Analysis
Healthcare Insight believes the strategic question is not simply:
“Did Zenbexus beat DVd on PFS?”
It is:
“Did the clinical benefit arrive after regulators acted early on the MRD signal?”
So far, the answer is yes.
EXCALIBER first showed substantially deeper molecular responses. The later PFS analysis now indicates that those responses were accompanied by a meaningful delay in progression or death.
That matters beyond Zenbexus.
If similar relationships are reproduced across additional randomized studies, MRD could become a more useful regulatory bridge in myeloma — allowing therapies to reach patients before waiting several years for traditional time-to-event endpoints to mature.
But EXCALIBER does not settle the surrogate question universally.
FDA still requires BMS to complete the randomized confirmatory study with PFS as the primary endpoint and overall survival and response outcomes among secondary measures. Continued approval remains contingent on verification of clinical benefit.
The second strategic story is CELMoD franchise construction.
Iberdomide builds on BMS’ long history with cereblon-targeting IMiDs but is designed as a more potent cereblon E3 ligase modulator and protein degrader. BMS is developing iberdomide not only in relapsed disease but also in post-transplant maintenance, while mezigdomide is being advanced in separate combinations.
The company is effectively attempting to move from:
IMiD legacy → next-generation CELMoD platform.
If successful, CELMoDs could become oral backbone agents that remain combinable with anti-CD38 antibodies, proteasome inhibitors and eventually newer immunotherapies.
The commercial challenge, however, is sequencing.
EXCALIBER excluded patients whose disease was refractory to prior anti-CD38 therapy or bortezomib. That matters because anti-CD38 antibodies are increasingly used earlier in the disease course.
The more daratumumab-exposed the real-world population becomes, the more important it will be to understand exactly where ZDd fits.
A second constraint is tolerability.
Although iberdomide is oral, the regimen should not be equated with low-intensity treatment. The Zenbexus safety profile includes substantial neutropenia, serious infections and thromboembolic risk, requiring monitoring and prophylactic management.
Convenience therefore needs to be evaluated against total treatment burden, not pill administration alone.
Market Implications
BMS: the PFS result materially de-risks Zenbexus and strengthens the broader CELMoD investment thesis.
J&J: Darzalex remains embedded as the anti-CD38 backbone of the winning regimen.
Regulators: EXCALIBER becomes an important real-world regulatory case study for MRD-based accelerated approval.
Competitors: future myeloma differentiation will increasingly require depth of response, durability, sequencing flexibility and operational convenience together.
ANALYTICAL MATRIX
| Dimension | Current Signal | Strategic Meaning | Remaining Question |
|---|---|---|---|
| MRD | 41% vs 21% | Earlier efficacy readout | How predictive is it of OS? |
| PFS | 42 vs 20 months; HR 0.49 | Clinical-benefit confirmation | Longer maturity |
| CELMoD | First approved member | New oral backbone class | Class durability |
| Population | 1–2 prior lines | Earlier-line opportunity | Anti-CD38-refractory setting |
| Safety | Significant hematologic/infectious risk | Requires active management | Real-world tolerability |
Zenbexus is therefore doing more than extending PFS.
It is connecting three layers of evidence that usually mature years apart: molecular response → regulatory access → progression benefit.
If overall survival and long-term safety eventually follow the same direction, EXCALIBER may become a case study not only for iberdomide, but for how multiple myeloma therapies can be developed and regulated faster in the MRD era.